Vol 50 No 08

"I tried to highlight how race has been used in medical research, specifically analyzing how this may [be] used toward Black people as a way to uphold systems of oppression," says Randy Vince, Jr., MD, MS.

Latest data indicate that approximately 8.5% of Part B payments were improper.

Conversion factor for 2023 is set to decrease by approximately 4.4%.

"This article serves as a summary of the literature published in the past 3 years, documenting the impact of exercise and physical activity on prostate cancer development and on cancer-specific, treatment-related, and patient-reported outcomes," writes Christine Ibilibor, MD, MSc.

Be sure to obtain a release before providing patient records.

In this interview, Catherine Ann Matthews, MD, FACS, FACOG, discusses the resurgence of single-incision slings and outlines a clinical trial of slings that she is currently leading.

Identifying your specific needs is a good starting point.

"With urge incontinence, the biggest advantage over the past few years is the emergence, and the proven efficacy, of the β-3 agonists, which are much better medications than the anticholinergic," says 1 urologist.

“Overall, these data…provide new insights about survival in patients receiving avelumab first-line maintenance in the JAVELIN Bladder 100 trial with or without second-line treatment," says Joaquim Bellmunt, MD, PhD.

“Cabozantinib plus atezolizumab demonstrated clinical activity with manageable toxicity in inoperable locally advanced or metastatic urothelial carcinoma," said lead author Sumanta K. Pal.

In this installment of Urology Times' 50th Anniversary Innovation Celebration, Sam S. Chang, MD, MBA, discusses the critical role that BCG has played in managing bladder cancer, and how the BCG shortage continues to evolve.